Unease about the economy drove many investors to snap up defensive stocks. Should you do the same?   Read More

The latest erectile dysfunction drug is showing promise of working even faster than those already on the market. Considering it's $3.5 billion market, what's the trade?   Read More

Trading desks idle as light volume continues. It started on November 1st — sell-side desks started seeing a drop in trading volume, and it has continued through the month. What gives?    Read More

This weekend, the US House of Representatives passed its version of health care reform and now awaits a version from the Senate.  The debate has been heating up since earlier this summer when President Obama was pushing for legislation before the summer recess.  Here are the biggest S&P Health Care gainers and losers over while the debate has waged on.   Read More

Over the past few days there's been a remarkable confluence of newsflow, most of it positive, out of biopharma. First the bad news.    Read More

Cramer makes the call on viewers' favorite stocks.   Read More

The folks at Eli Lilly probably cringe every time I go here, but the company this morning reported that third quarter U.S. sales of the erectile dysfunction drug Cialis sprung 13 percent to nearly $159 million.    Read More

Cramer makes the call on viewers' favorite stocks.   Read More

Following my post earlier this week on the highest yielding stocks in the Dow, here is a deeper look at the dividends of the S&P 500.   Read More

Dendreon is growing in more ways than one. At a time when so many drug companies are letting people go, Dendreon is on a hiring binge to ramp up for the anticipated launch of its prostate cancer drug Provenge. But it's also expanding its board of directors.    Read More